News & Updates
Filter by Specialty:
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023
COVID-19 vaccines may elicit cross-reactive T-cell responses for long-term protection
Researchers from the Chinese University of Hong Kong (CUHK) have reported that two doses of either mRNA-based BNT162b2 or inactivated CZ02 vaccine elicit cross-reactive T-cell responses. Identification of vaccine-induced memory T cells indicates potential long-term protection with COVID-19 vaccines.
COVID-19 vaccines may elicit cross-reactive T-cell responses for long-term protection
01 Aug 2023
Minimal monitoring feasible in HCV patients on SOF/VEL
Minimal monitoring is feasible in patients with active hepatitis C virus (HCV) infection treated with sofosbuvir/velpatasvir (SOF/VEL), with high rates of sustained virologic response (SVR) reported, including in patients with novel HCV subtypes, according to new data from the phase IV MINMON study presented at IDDF 2023.